Browse the evidence

High-intensity exercise training (77-95% max HR or 14-17 Borg scale) improves walking performance and cardiorespiratory fitness more effectively than low-intensity training in PAD patients.

If you can tolerate it, aim for high-intensity walking during your supervised sessions. Use a heart rate monitor or the Borg scale (14-17) to guide your effort. This approach yields the best improvements in how far and how well you can walk.

A 12-week daily supplementation with a multi-ingredient formula containing forskolin, green coffee bean extract, green tea extract, beet root extract, alpha-lipoic acid, vitamin E, and CoQ10 significantly reduces body weight and fat mass in overweight and obese adults compared to a placebo.

If you are overweight or obese, adding this specific multi-ingredient supplement to your daily routine for 12 weeks may help you lose about 2-3 kg more than if you took a placebo, even without changing your diet or exercise habits. However, for best results, use it as a support to healthy eating and activity, not a substitute.

Semaglutide 2.4 mg/week induces significant weight loss in patients with severe obesity, including those with a history of bariatric surgery, achieving outcomes comparable to or exceeding those of non-surgical patients.

If you have severe obesity, even if you have had weight loss surgery before, a weekly injection of 2.4 mg semaglutide can still help you lose weight. It is not a wasted effort due to your surgical history.

Regular exercise prevents and treats cardiometabolic diseases, including obesity, type 2 diabetes, and cardiovascular disease, through pleiotropic effects on cardiorespiratory fitness and metabolic homeostasis.

Incorporate regular, structured physical activity into your routine to protect your heart and metabolic health. Focus on improving your cardiorespiratory fitness through a mix of aerobic and resistance exercises, as this combination is often more beneficial than either alone, especially for managing type 2 diabetes.

In adults with type 2 diabetes and overweight or obesity, maintaining high physical activity volume combined with weight loss significantly reduces the risk of adverse cardiovascular events, whereas either intervention alone does not.

If you have type 2 diabetes and are overweight, relying on just losing weight or just exercising may not be enough to protect your heart. You need to do both: maintain a significant weight loss (at least 7%) AND keep your physical activity levels high (moderate-to-vigorous) over the long term. This combination offers a much stronger defense against heart attacks and strokes than either strategy alone.

Skeletal Muscle Mass (SMM) and Appendicular Lean Soft Tissue (ALST) are critical protective factors against frailty, diabetes, and mortality, and their loss (sarcopenia) is an independent risk factor for adverse health outcomes.

Prioritize resistance training to build and maintain muscle mass, especially as you age. Muscle is not just for aesthetics; it is your primary organ for glucose disposal and metabolic health. If you are losing weight, ensure you are doing resistance training and consuming adequate protein to prevent muscle loss, which can lead to frailty and weight regain.

Long-term use of GLP-1 receptor agonists (semaglutide 2.4mg or tirzepatide 15mg) produces significant weight loss (4-21%) and improved cardiometabolic markers, but discontinuation leads to rapid weight regain and increased cardiac risk.

GLP-1 agonists like Wegovy and Mounjaro are highly effective for significant weight loss (up to 20%) when taken long-term. However, they are not a 'cure'; stopping the medication typically results in weight regain and increased heart disease risk. If you use these, view them as a long-term tool alongside lifestyle changes, not a quick fix.

Combining GLP-1 agonist therapy with exercise and diet reduces abdominal fat and metabolic syndrome severity more effectively than medication alone, without increasing hypoglycemia risk.

Taking GLP-1 medications works best when paired with exercise and healthy eating. This combination specifically targets abdominal fat and improves heart health markers without raising blood sugar risks. Do not skip lifestyle changes just because you are on medication.

Structured behavioral lifestyle interventions (BLIs) with frequent feedback and support produce clinically meaningful weight loss (≥5%) in overweight or obese patients with type 2 diabetes, regardless of specific diet or exercise components.

For T2DM patients, the specific diet or exercise type matters less than the structure of the support. Choose a program that offers frequent feedback, regular monitoring, and social support. Consistency in attending sessions and receiving feedback is more critical than the specific 'brand' of diet or exercise.

Time-restricted eating (TRE) with a 9-hour eating window (1000–1900 h) is non-inferior to standard individualized dietetic guidance for improving HbA1c and glycemic control in adults with type 2 diabetes over a 6-month period.

If you have type 2 diabetes, try limiting your daily eating to a 9-hour window, specifically between 10:00 AM and 7:00 PM. You do not need to restrict calories explicitly, but you will likely eat less spontaneously. This approach is just as effective as standard dietitian advice for lowering HbA1c and may be easier to stick with because it is simpler. Ensure you are not on medications that require strict meal timing (like insulin or sulphonylureas) without medical supervision.

Animal protein improves muscle mass compared to non-soy plant proteins (rice, chia, oat, potato) and plant-based diets, while soy protein is equivalent to milk protein for muscle mass.

If you are using plant protein, soy is just as good as animal protein for building muscle. Other plant proteins (rice, pea, oat, potato) may be less effective, so consider combining them or supplementing with soy or animal protein if muscle mass is a priority.

Multimodal interventions combining structured resistance and endurance exercise with adequate protein and caloric intake are effective for preventing and treating frailty in community-dwelling older adults.

For older adults with frailty, engage in a supervised, multimodal exercise program at least 2-3 times per week for 12 weeks or more. Combine resistance training (using weights or bodyweight, progressing to 20-85% of your one-rep max) with endurance activities (120-300 minutes of light-to-moderate activity weekly). Ensure your diet provides adequate calories and protein to support muscle repair. Consult a healthcare provider for a comprehensive assessment before starting.

Reducing ultra-processed food intake after a colorectal cancer diagnosis is associated with lower cardiovascular disease mortality compared to maintaining or increasing UPF intake.

If you have had colorectal cancer, cutting back on ultra-processed foods after your diagnosis can significantly lower your risk of dying from heart disease. Even a moderate reduction (e.g., 2-3 servings per day less than before) is associated with better outcomes.

Combining incretin-based obesity medications (semaglutide/tirzepatide) with moderate lifestyle modification (150 min/week aerobic + 2 days resistance) yields sustainable weight loss and health benefits, making intensive behavioral therapy and strict caloric restriction redundant.

If you are prescribed semaglutide or tirzepatide, you do not need to follow a strict diet or exercise for hours every day. Aim for 150 minutes of moderate walking per week and two days of strength training. This moderate approach is sufficient to maintain weight loss and health benefits alongside your medication, whereas intensive protocols are likely unnecessary and harder to sustain.

Losing obesity (achieving non-obesity status) after having been obese in young adulthood normalizes the risk of MASLD, at-risk MASH, and increased liver stiffness to levels comparable to those who were never obese.

If you were obese in your young adulthood but have since lost the weight to a non-obese range, your risk for serious liver conditions (like MASH and fibrosis) is likely the same as someone who was never obese. You do not need to worry about 'permanent' liver damage from your past obesity if you have achieved and maintained a healthy weight.

Semaglutide (GLP-1 receptor agonist) produces significant weight loss (15.5% in adolescents, 12.5% in adults) and cardiovascular benefits, making it a prioritized treatment for those with metabolic risk factors.

Semaglutide is a highly effective weekly injection that can lead to significant weight loss (12-15%) and cardiovascular benefits. It is particularly recommended for those with metabolic risks or low satiety.

A greater reduction in intrahepatic fat content (IFC) following a 6-month lifestyle intervention (Mediterranean diet and physical activity) is associated with improved oxidative stress and inflammatory status, specifically through increased catalase activity and reduced irisin and cytokeratin-18 levels, alongside better cardiorespiratory fitness.

For NAFLD patients, achieving a significant reduction in liver fat through a 6-month lifestyle program involving a calorie-restricted Mediterranean diet and regular physical activity (either high steps or interval training) leads to better oxidative stress and inflammatory profiles. Focus on adherence to the diet and increasing activity levels to maximize liver fat loss.

A low-carbohydrate, ketogenic diet (<20 g carbohydrate/day) produces significantly greater weight loss and improves lipid profiles (lower triglycerides, higher HDL) compared to a low-fat, reduced-calorie diet over 24 weeks in overweight, hyperlipidemic adults.

If you are overweight and have high cholesterol, switching to a very low-carb diet (under 20g carbs/day) for 6 months will likely result in nearly double the weight loss compared to a standard low-fat diet, while significantly improving your triglyceride and HDL levels. You do not need to count calories strictly, but you must avoid grains, sugars, and most fruits initially. Expect some initial side effects like fatigue or constipation, which can be managed with water, salt, and supplements. Monitor your LDL cholesterol, as a minority of people may see it rise.

Moderate and sustained weight loss through combined diet, exercise, and lifestyle modifications improves blood glucose levels, insulin action, and reduces the need for diabetic medications in individuals with obesity and type 2 diabetes.

If you have obesity and Type 2 Diabetes, losing weight is the most critical step you can take to improve your health. You don't need a specific pill or extreme diet; focus on a sustainable combination of eating less, moving more, and changing daily habits. This approach directly improves how your body handles sugar and insulin, potentially reducing your need for medication.

Increasing daily protein intake to ≥1.6 g/kg/day enhances lean body mass gains in healthy adults under 65 years old who perform resistance exercise, whereas older adults (≥65) achieve significant gains at lower intakes (1.2–1.59 g/kg/day).

If you are under 65 and lifting weights, aim for at least 1.6 grams of protein per kilogram of body weight daily to maximize muscle growth. If you are 65 or older, you may see significant muscle benefits with a slightly lower intake of 1.2 to 1.6 grams per kilogram. This assumes you are doing resistance exercise; protein alone without exercise has minimal impact on muscle mass in healthy adults.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, significantly reduces body weight (exceeding 20% in some contexts) and improves glycemic control (HbA1c) in patients with Type 2 Diabetes and Obesity when administered via subcutaneous injection once weekly.

Tirzepatide is a once-weekly subcutaneous injection approved for Type 2 Diabetes and Obesity. It works by mimicking two gut hormones (GLP-1 and GIP) to improve insulin sensitivity and reduce appetite. Clinical trials show it leads to significant weight loss (often >20%) and better blood sugar control than some existing drugs like semaglutide. Common side effects like nausea are usually temporary and managed by starting with a low dose and increasing slowly. It is not a standalone cure but works best with lifestyle changes.

Semaglutide 2.4 mg is a cost-effective treatment for obesity and overweight in the US, providing greater weight loss and QALYs than diet/exercise, no treatment, or other anti-obesity medications, provided the willingness-to-pay threshold is $150,000 per QALY.

For patients with obesity or overweight plus comorbidities, semaglutide 2.4 mg combined with diet and exercise is a cost-effective medical option in the US, offering significant weight loss and quality-adjusted life years compared to lifestyle changes alone or other medications, assuming a willingness-to-pay threshold of $150,000 per QALY.

Anti-obesity medications (AOMs) are effective adjuncts for weight reduction and treating adiposopathy, but their efficacy is contingent upon adherence and individual metabolic response, with weight regain occurring if treatment is discontinued.

Use FDA-approved anti-obesity medications as a long-term tool to manage obesity, not just for short-term weight loss. They work best when combined with nutrition and exercise. Do not stop the medication just because you hit a target weight; stopping often leads to regain. Discuss specific drugs (like Semaglutide or Phentermine) with your doctor based on your health profile.

Sustained weight loss of at least 15% significantly improves glycemic control, reduces cardiometabolic risk, and can induce remission of Type 2 Diabetes (T2DM).

To potentially reverse Type 2 Diabetes, aim for a sustained loss of 15% or more of your body weight. This threshold is linked to significant improvements in blood sugar control and reduced heart disease risk. Be aware that maintaining this loss is biologically challenging due to appetite changes, so long-term strategies (like medication or surgery) may be necessary to support this goal.